Previewing the European Association for the Study of Diabetes 2022 Annual Conference
The diaTribe Learn team is headed to Stockholm, Sweden, to cover the latest news in diabetes research, drug development, care, and technology being presented at this year's European Association for the Study of Diabetes (EASD) conference. Here are some of the sessions we plan to attend.
The future of diabetes medications will be one of the most highly anticipated topics at EASD 2022. Global experts will share evidence on how new drugs affect glucose management, weight loss, and prevent long-term complications.
While the official conference sessions kick off on Tuesday, the team has already started attending Monday sessions filled with updates on diabetes medications from several industry participants.
Tuesday morning begins with a session about incretin therapies (incretins work by mimicking the hormones that the body usually produces naturally to stimulate the release of insulin in response to a meal) and what lies ahead for these amazing drugs.
Two sessions will cover the results from several large clinical trials for tirzepatide, which is sold under the brand name Mounjaro (you might recall our coverage of the note-worthy results from the SURPASS-1 trial shared at this year’s ADA conference in New Orleans). We anticipate even more news about this new drug’s impact on weight loss and diabetes complications.
Another presentation will share new data on the effects of semaglutide (sold as Ozempic, Rybelsus, and Wegovy) on the progression of heart disease.
We look forward to a discussion about the future of once-weekly insulin as well as the potential benefits of drugs approved by the FDA for people with Type 2 but not people with Type 1 because of the risk of hypoglycemia.
Diabetes Technology and Prevention
Several sessions will focus on new data and the future of diabetes technology including the benefits of automated insulin delivery (AID) systems and what to anticipate in the near future for diabetes technology. Another session will explore the current state of technology for people with type 1 diabetes.
A symposium on prevention will explore the definition of type 2 diabetes remission and the latest strategies to make remission a reality for people with type 2. Experts will also discuss the possibility of the prevention of type 1 diabetes and treatments in development that may be approaching FDA approval.
Updates on Time in Range
As more and more healthcare providers and researchers incorporate time in range (TIR) into their discussions about daily glucose management, the conversation about TIR will be included in a number of sessions throughout the week. A symposium featuring some of the top global leaders in diabetes care will explore how healthcare providers and people with diabetes can integrate TIR data into their conversations about their glucose management.
We will also cover two separate presentations from diaTribe senior associates, Natalie Sainz and Arvind Sommi, who will discuss the different types of TIR resources used by healthcare providers, as well as how the perceived benefits of TIR vary between health care providers and people with diabetes.
Solvable Problems in Diabetes
On Tuesday evening, Sept. 20, diaTribe will host its 9th Annual Solvable Problems in Diabetes panel discussion, live for the first time since 2019. The theme of this year’s all-female panel is “The Renaissance in Diabetes Technology and Therapies: Opportunities Abound, Challenges Remain.”
This year’s panelists are world-renowned experts in diabetes care; they plan to explore a variety of topics including advances in diabetes technology, therapies to reduce the risk of complications, prevention and delay of type 1 diabetes, and recent breakthroughs in beta cell therapies and potential cures for type 1 diabetes.
Keep an eye out for our Friday special edition mailer on September 23, where we will share the most exciting news and highlights from the first few days of the conference followed by our full conference coverage on Tuesday September 27, so stay tuned for more!